ArticleResearch in pharmaceutical sciences2026
Novel nanoliposomes for targeted codelivery of three anticancer agents against head and neck squamous cell carcinoma.
Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Head and neck squamous cell carcinoma (HNSCC) is a malignant tumor in which the overexpression of epidermal growth factor receptor (EGFR) is associated with malignancy. For the treatment of HNSCC, cetuximab (CIT) as an anti-EGFR antibody is prescribed in combination with anticancer chemotherapy drugs for greater effectiveness. Experimental approach: In this work, a CIT-targeted immunoliposome loaded with cisplatin (CP) and docetaxel (DTX) was developed to allow co-administration of the antibody and the anticancer chemotherapy drugs and selective delivery to HNSCC cells. Developed immunoliposomes were characterized for particle sizes, PDI, zeta potential, surface morphologies, and encapsulation efficiency. Moreover, additional Findings/Results: The final targeted liposomes exhibited an average diameter of 68.65 ± 3.4 nm; PDI and zeta- potential were respectively around -7.9 ± 1.7 mV and 0.35 ± 0.05. The encapsulation efficacy of DTX and CP within the immunoliposomes was approximately 95 ± 4% and 85 ± 4%, respectively. Flow cytometric analysis revealed that the cellular uptake rate of final immunoliposomes was significantly higher than that of the naked liposomes, indicating that CT conjugation on the surface of nanoliposomes facilitated higher accumulation Conclusions and implications: The results indicated that nanoliposomes anchored with CIT enhanced drug accumulation and cytotoxicity in cancer cells and reduced the likelihood of adverse side effects, paving the way for more effective cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.